The Apolipoprotein B/A1 Ratio is Associated with Reactive Oxygen Metabolites and Endothelial Dysfunction in Statin-Treated Patients with Coronary Artery Disease

被引:12
作者
Emoto, Takuo [1 ]
Sawada, Takahiro [1 ]
Morimoto, Natsumi [2 ]
Tenjin, Takako [2 ]
Wakimoto, Taku [2 ]
Ikeda, Fumie [2 ]
Sato, Chiaki [2 ]
Terashita, Daisuke [1 ]
Mizoguchi, Taiji [1 ]
Mizuguchi, Takao [1 ]
Okamoto, Hiroshi [1 ]
Matsuo, Yosuke [1 ]
Kim, Sushi-ku [1 ]
Takarada, Akira [1 ]
Yokoyama, Mitsuhiro [3 ]
机构
[1] Hyogo Prefectural Awaji Hosp, Dept Internal Med, Div Cardiovasc Med, Sumoto, Hyogo 6560013, Japan
[2] Hyogo Prefectural Awaji Hosp, Dept Inspect, Sumoto, Hyogo 6560013, Japan
[3] Hyogo Brain & Heart Ctr, Dept Cardiol, Kobe, Hyogo, Japan
关键词
ApoB/A1; ratio; d-ROMs test; Endothelial dysfunction; PRIMARY PREVENTION; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; EICOSAPENTAENOIC ACID; MYOCARDIAL-INFARCTION; RISK; PREDICTION; ATHEROSCLEROSIS; ATORVASTATIN; MORTALITY;
D O I
10.5551/jat.16824
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim: The prognostic significance of the apolipoprotein B/A1 (ApoB/A1) ratio in statintreated patients with coronary artery disease (CAD) is unknown. We aimed to evaluate the association of the ApoB/A1 ratio with oxidative stress and endothelial dysfunction in these patients. Methods: We enrolled 62 consecutive statin-treated patients who underwent percutaneous coronary intervention (PCI). Their lipid profiles, diacron-reactive oxygen metabolites (d-ROMs), as a marker of oxidative stress, flow-mediated dilatation (FMD), as a marker of vascular endothelial function, and C-reactive protein (CRP) levels, as a marker of inflammation, were measured. Results: Our study population comprised 44 men and 18 women (mean age, 70.5 +/- 2.5 years). The ApoB/A1 ratio was positively correlated with the results of the d-ROMs test (p=0.004, r = 0.36) and CRP level (p=0.02, r = 0.30) and negatively correlated with the % FMD (p=0.005, r = -0.40). A multivariate logistic regression analysis showed that the most powerful predictive factor for the d-ROMs was the ApoB/A1 ratio (p=0.026). We therefore divided patients into two groups according to the cutoff point reported by the INTERHEART study: a low ApoB/A1 ratio (<0.641, n=26) and a high ApoB/A1 ratio (>0.641, n=36). The patients with a high ApoB/A1 ratio had higher levels of d-ROMs and CRP, and tended to have a lower %FMD. Conclusion: The ApoB/A1 ratio was associated with the d-ROMs, a marker of oxidative stress, endothelial dysfunction and inflammation, and could be useful as a residual atherosclerotic risk marker to help prevent CAD in statin-treated patients.
引用
收藏
页码:623 / 629
页数:7
相关论文
共 23 条
[1]   Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) [J].
Ballantyne, Christie M. ;
Bays, Harold E. ;
Kastelein, John J. ;
Stein, Evan ;
Isaacsohn, Jonathan L. ;
Braeckman, Rene A. ;
Soni, Paresh N. .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (07) :984-992
[2]   International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS [J].
Caro, J ;
Klittich, W ;
McGuire, A ;
Ford, I ;
Pettitt, D ;
Norrie, J ;
Shepherd, J .
EUROPEAN HEART JOURNAL, 1999, 20 (04) :263-268
[3]  
Cesarone MR, 1999, INT ANGIOL, V18, P127
[4]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[5]   Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force [J].
Corretti, MC ;
Anderson, TJ ;
Benjamin, EJ ;
Celermajer, D ;
Charbonneau, F ;
Creager, MA ;
Deanfield, J ;
Drexler, H ;
Gerhard-Herman, M ;
Herrington, D ;
Vallance, P ;
Vita, J ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :257-265
[6]   A Review of the Current Status of the Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and Metabolic Syndrome [J].
Davidson, Michael .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (12A) :19L-27L
[7]   Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study [J].
Eliasson, B. ;
Moeller-Goede, D. ;
Eeg-Olofsson, K. ;
Wilson, C. ;
Cederholm, J. ;
Fleck, P. ;
Diamant, M. ;
Taskinen, M. -R. ;
Smith, U. .
DIABETOLOGIA, 2012, 55 (04) :915-925
[8]   Effect of 3-Month Repeated Administration of Miglitol on Vascular Endothelial Function in Patients With Diabetes Mellitus and Coronary Artery Disease [J].
Emoto, Takuo ;
Sawada, Takahiro ;
Hashimoto, Megumi ;
Kageyama, Hiroko ;
Terashita, Daisuke ;
Mizoguchi, Taiji ;
Mizuguchi, Takao ;
Motodi, Yoshiki ;
Iwasaki, Masamichi ;
Taira, Kazuki ;
Okamoto, Hiroshi ;
Matsuo, Yosuke ;
Kim, Sushi-ku ;
Takarada, Akira ;
Yokoyama, Mitsuhiro .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (01) :42-46
[9]   Significance of measuring oxidative stress in lifestyle-related diseases from the viewpoint of correlation between d-ROMs and BAP in Japanese subjects [J].
Fukui, Toshiki ;
Yamauchi, Kazuhiro ;
Maruyama, Mie ;
Yasuda, Tadashi ;
Kohno, Masakazu ;
Abe, Youichi .
HYPERTENSION RESEARCH, 2011, 34 (09) :1041-1045
[10]   Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) [J].
Knopp, Robert H. ;
D'Emden, Michael ;
Smilde, Johan G. ;
Pocock, Stuart J. .
DIABETES CARE, 2006, 29 (07) :1478-1485